
|Articles|November 22, 2013
BBK Worldwide Builds on Tablet Function in Latest Version of Study eBinder
Author(s)Lisa Henderson
BBK Worldwide announced the latest version its Study eBinder
Advertisement
BBK Worldwide announced the latest version its Study eBinder, which addresses more customization for its tablet that study teams use. Version 3.0 provides more than 300 real-time reports and a protected instant messaging system for sponsors to connect directly with physician investigators and site staff in its proprietary patient recruitment portal, TrialCentralNet (TCN®). The new version also is fully customizable for the sponsor's brand and content.
You can read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Nipocalimab Delivers Positive Phase IIb Results in JASMINE SLE Trial
2
BostonGene Expands AI-Driven Oncology Collaborations with New AstraZeneca Deal
3
ACT Brief: Rethinking Representation in Cancer Trials, Positive Phase IIb SLE Data, and a Major Obesity Drug Partnership
4
Fresh Starts, Real Readiness: Turning Site Initiation into a Trial Success Multiplier
5



